Proxima

• Teams seeking a self-serve software product with published pricing and end-user reviews
• Programs requiring immediate clinical-stage assets rather than discovery platform collaboration

• Vendor materials note that retrospective evaluations have limitations and that prospective experimental validation will be shared later.

• No explicit public roadmap with dated deliverables was found; public updates are provided primarily via news releases.

• Not publicly documented in available materials.

• No public SOC 2 or ISO 27001 materials were found for proximabio.com.

• NeoLink XLMS is described as a higher-throughput structural interaction data engine that aims to generate large-scale interaction restraints.
• Neo-1 is described as a model that unifies structure prediction and all-atom molecular generation, which can be conditioned on multimodal structural prompts.
• The vendor describes a data feedback loop in which additional experimental data improves model outputs and vice versa.

• Funding and partner interest are documented in press releases and news coverage.
• Technical superiority claims (for example, coverage, throughput, and end-to-end performance) are not independently validated in the public materials reviewed; these remain areas for focused due diligence.

• Gartner Peer Insights: No relevant listing for the vendor site found in accessible results.
• G2 / TrustRadius: No relevant vendor-site profile found; search results are dominated by unrelated "Proxima" products/brands.

Interpretation: This is expected—Proxima operates as a biotech platform company rather than a commercial SaaS product with consumer-oriented review profiles.

Direct end-user "customer review" style content about the company's site is scarce.

There is hiring-era visibility for the company under its prior name (VantAI) on aggregator pages that index Hacker News "Who is hiring?" posts. These postings describe a machine-learning-first biotech working on targeted protein degradation and infrastructure, which can provide an external signal about technical direction and hiring priorities.

Proxima’s Neo-1 page provides technical narratives and example reconstructions (for example, glue-induced ternary complexes assembled from XLMS-guided data).

Critical evaluation:

• The vendor notes retrospective evaluations have inherent limitations and that prospective experimentally validated results are expected later.
• Without peer-reviewed publication and external replication, performance claims should be treated as provisional.

• Mid-size biotech to large pharmaceutical companies (typically larger pharmaceutical organizations for pharma partners; venture-backed biotechs are also possible partners).

• Oncology, immunology, and other therapeutic areas where addressing traditionally "undruggable" targets and rewiring protein interactions are priorities.

• Heads of Discovery, Translational Science, and Medicinal Chemistry
• Business development and alliance management leads
• Computational chemistry and structural biology leadership

• Difficulty systematically discovering molecular glues
• Limited scalable experimental structural interaction data
• Need to accelerate early hit discovery and target–effector pairing

• Organizations willing to engage in long-term discovery collaborations
• Partners with downstream experimental and clinical capabilities to translate candidates
• Strategic interest in induced proximity approaches beyond classic inhibition

Proxima operates as a platform-focused biotech organization that realizes value primarily through:

• internal pipeline creation and advancement; and
• research collaborations and alliances with biopharma partners.

Its positioning aligns with a "TechBio" approach: combining proprietary experimental data generation with computational modeling to accelerate discovery of proximity modulators.